Mark Vickers

Mark F. Vickers PhD

Partner

Executive Summary

Mark F. Vickers, PhD, is a Partner, registered patent agent, and member of BLG's Intellectual Property Group & National Biotech and Pharmaceutical Group.

Mark acts for innovative and groundbreaking start-ups, Universities, Research Institutions, entrepreneurs, and multinational corporations, providing strategic advice on IP acquisition and portfolio development.

Mark's practice includes the preparation and prosecution of patent applications, plant breeders' rights applications, and industrial design applications.

Mark counsels clients on technologies relating to biotechnology, agriculture, and chemisty, in various sectors, including human and veterinary therapeutics and diagnostics, agricultural sciences, small molecules, pharmaceuticals, oil and gas, and alternative energy.

Based in Ottawa, Mark works with members of BLG's intellectual property, corporate law, financial services, regulatory, and IP litigation groups, across the country, to assemble a BLG Team to provide business critical advice.

Mark has been recognized in the 2017, 2016, 2015, and 2014 editions of IAM Patent 1000 – The World's Leading Patent Practitioners.

Mark carried out doctoral and postdoctoral research in biochemistry and oncology, and gained experience in anti-cancer vaccine development at a Canadian biotechnology company.

Representative Work

  • Preparation and prosecution of patent applications, plant breeders' rights applications, and industrial design applications.
  • Counseling clients on technologies relating to biotechnology, agriculture, and chemistry, in various industry sectors, including human and veterinary therapeutics and diagnostics, agricultural sciences, small molecules, pharmaceuticals, oil and gas, and alternative energy.
  • Advising on patentability, validity, infringement and freedom-to-operate issues.
  • Conducting intellectual property due diligence.
  • Counselling clients on international patent strategies and portfolio management.
  • Advising and assisting with Canadian University technology transfer.

Publications & Presentations

  • Co-Author, "Canadian Patent Office misses the mark on diagnostics," Biotechnology Focus, February/March 2016.
  • Co-Author, "Navigating the Patent Prosecution Highway in Canada," Life Sciences Canada, 2014 (with Jennifer Raoul).
  • ​King, Damaraju, Vickers et al., “A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems,” Molecular Pharmacology, 2006, 69(1): 346-53.
  • Vickers et al., “Uridine recognition motifs of human equilibrative nucleoside transporters 1 and 2 produced in saccharomyces cerevisiae,” Nucleosides, Nucleotides and Nucleic Acids, 2004, 23.
  • Zhang, Visser, Vickers et al., “Uridine Binding Motifs of Human Concentrative Nucleoside Transporters 1 and 3 Produced in Saccharomyces cerevisiae,” Molecular Pharmacology, 2003, 64:1512-20.
  • Vickers et al.,“Comparison of the interaction of uridine, cytidine and other pyrimidine nucleoside analogues with recombinant human equilibrative nucleoside transporter 2 (hENT2) produced in Saccharomyces cerevisiae,” Biochemistry and Cell Biology, 2002, 80: 639-644
  • Yao, Ng, Vickers et al.,“Functional and molecular characterization of nucleobase transport by recombinant human and rat ENT1 and ENT2 equilibrative nucleoside transport proteins: Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation,” Journal of Biological Chemistry, 2002, 277: 24938-48.
  • Visser, Vickers et al.,“Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole,” Journal of Biological Chemistry, 2001, 277: 395-401.
  • Vickers et al., “Functional production of mammalian and bacterial members of the concentrative nucleoside transporter (CNT) family of membrane proteins in Saccharomyces cerevisiae,” Molecular Membrane Biochemistry, 2000, 18: 73-79.
  • Vickers et al., “Nucleoside transporter proteins of Saccharomyces cerevisiae: Demonstration of a transporter (FUI1) with high uridine selectivity in plasma membranes and a transporter (FUN26) with broad nucleoside selectivity in intracellular membranes,” 2000, Journal of Biological Chemistry, 34: 25931-38.
  • Vickers et al., “Nucleoside transporter proteins: emerging targets for drug discovery,” 2000, Emerging Therapeutic Targets, 4: 515-39.
  • Jennings, Hao, Cabrita, Vickers et al., “Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system,” Neuropharmacology, 2000, 40: 722-31.
  • Vickers et al., “Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae: binding of nitrobenzylthioinosine to recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q),” Biochemical Journal, 1999, 339: 21-32.
  • Hogue, Ellison, Vickers & Cass, “Functional complementation of a membrane transport deficiency in Saccharomyces cerevisiae by recombinant ND4 fusion protein,” Biochem. Biophys. Res. Commun, 1997, 238: 811-16.
  • Lu, Vickers & Kerbel, “Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression,” Proceedings of the National Academy of Sciences USA, 1992, 89: 9215-19.

Rankings & Recognitions

  • ​Recognized in the 2017, 2016, 2015 and 2014 editions of IAM Patent 1000 — The World's Leading Patent Practitioners (Patent Prosecution).